Services
Providing Advanced Biological Technical Services for Researchers in Fundamental Science
Yeast Two-Hybrid VHH Nanobody Screening and Discovery Services
Technology Overview
The customized Nanobody Screening Nuclear System developed by ProNet Biotech provides a fast, efficient, and reliable method to screen and identify nanobodies that function in the nucleus. This service facilitates a deeper understanding of the functions and interaction mechanisms of nuclear proteins, thereby accelerating research progress in various fields, including cell biology, molecular biology, and drug discovery.
Nanobodies, also known as single-domain antibodies or VHH (variable domain of heavy-chain antibody), are a unique class of antibodies that lack light chains and have a variable heavy chain domain (VHH) capable of independent expression. Despite their small size, with a crystal width of just 2.5 nm, a length of 4.8 nm, and a molecular weight of approximately 15 kDa, nanobodies exhibit antigen-binding activities comparable to conventional antibodies, making them the smallest known antigen-binding units.
Key characteristics of nanobodies include:
1. Unique Antigen-Binding Properties:
The complementarity-determining region 3 (CDR3) of nanobodies is similar to or longer than that of the human VH domain, enabling strong and specific interactions.
Their finger-like structures can access cavities or hidden epitopes not available to monoclonal antibodies (mAbs).
2. Superior Stability and Solubility:
Nanobodies maintain their binding affinity across a wide range of conditions due to excellent hydrophilicity and water solubility.
These properties make nanobodies an indispensable tool for early and rapid disease diagnosis, as well as for detecting highly pathogenic, infectious, and potentially deadly pathogens.
| Performance | Traditional Antibodies | Nanobodies |
|---|---|---|
| Antibody Expression | Mammalian expression, high cost | Prokaryotic and eukaryotic expression, high yield, low cost |
| Antibody Stability | Prone to inactivation | Highly soluble, extremely stable |
| Immunogenicity | High | Low |
| Tissue Penetration | Low | High, capable of crossing the blood-brain barrier and penetrating dense tissues |
Service Content
We offer a comprehensive and customizable service package for nanobody screening using the yeast two-hybrid (Y2H) system:
| Yeast Two-Hybrid VHH Screening (Nuclear System) | ||
Steps | Working days | Deliverables |
1. Gene synthesis(Codon Optimization) | 15 | 1. Sequencing results of positive clones (subject to sequencing outcomes). 2. ≥ 8 CDR3. 3. A comprehensive electronic project report in Word format, including experimental data. 4. Bait plasmids (Optional). |
2. Self-activation test of bait plasmid | 10 | |
3. Co-transfer bait plasmid and VHH library plasmid 4. Selective medium for yeast screening 5. Sanger sequencing of screening results |
20
| |
6. Rotation and verification of screening results 7. Complete project data report | 5 | |
Total | 50 | |
| Yeast Two-Hybrid VHH Screening (Membrane System) | ||
Steps | Working days | Deliverables |
| 1. Transmembrane Structure Analysis | ＜1 | 1. Sequencing results of positive clones (Based on sequencing outcomes). 2. ≥ 8 positive clone sequences with no frameshift mutations. 3. A comprehensive electronic project report in Word format, including experimental data. 4. Bait plasmids (Optional). |
2. Gene synthesis(Codon Optimization) | 15 | |
3. Self-activation test of bait plasmid | 10 | |
4. Co-transfer bait plasmid and VHH library plasmid 5. Selective medium for yeast screening 6. Sanger sequencing of screening results |
20
| |
7. Rotation and verification of screening results 8. Complete project data report | 5 | |
Total | 50 | |
Features and Advantages
· Synthetic VHH Library:
Library includes over 10⁸ full-length nanobody clones, ensuring high diversity and no frameshift mutations.
Based on camelid antibodies with engineered diversity in CDR1, CDR2, and CDR3 regions for robust antigen binding.
· Dual Validation Process:
Conducted on both three-deficiency (SD-Trp/-Leu/-His) and four-deficiency (SD-Trp/-Leu/-His/-Ade) media to ensure the reliability of screening results.
· Cost-Effective:
Offers accuracy comparable to phage display screening at a significantly lower cost.
· Comprehensive Deliverables:
Complete experiment reports, result images, annotated VHH structures (CDR1, CDR2, CDR3 regions), and bioinformatics analysis.
· Post-Sales Support:
Expert consultation and guidance to ensure maximum satisfaction.
Applications
Identification of nanobodies with specific binding to nuclear proteins.
High-throughput screening for drug target validation.
Early disease diagnosis and pathogen detection.
Structural and functional analysis of protein interactions.
Why Choose ProNet Biotech?
ProNet Biotech leverages cutting-edge yeast two-hybrid technology combined with a robust synthetic VHH library to deliver unparalleled screening services. Our dedicated team ensures high-quality results and supports your research needs with precision and expertise.
Contact Us
Ready to accelerate your nanobody discovery journey? Contact our experts today to discuss your project and receive a customized quote!
Services Workflow
Online Consultation
01
Solution Matching
02
Service Contract
03
One-Stop-Services
04
Project Report
05
Related Products
Product Inquiry
Contact Us
Tel: +86 025-85205672
Email: info@pronetbio.com
Address: Building 3C, Nanjing Xianlin Zhigu,
Qixia District, Nanjing, Jiangsu, China, 210033
Need more information?
Let's connect!